Clopidogrel: A Case for Indication-Specific Pharmacogenetics

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

(2011) S A Scott et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

(2011) Michael V. Holmes et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacogenomics and Clopidogrel

(2011) Steven E. Nissen   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

(2010) Jessica L. Mega et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

(2010) Jean-Sébastien Hulot et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment

(2010) Guillaume Paré et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

(2009) Alan R. Shuldiner   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

(2008) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE